Quarterlytics / Healthcare / Drug Manufacturers - Specialty & Generic / N4 Pharma Plc

N4 Pharma Plc

n4p · LSE Healthcare
Claim this profile
Ticker n4p
Exchange LSE
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Employees 1-10
← All annual reports
FY2016 Annual Report · N4 Pharma Plc
Sign in to download
Loading PDF…
ULTIMA NETWORKS PLC 

                                                                                                   Company Number 01435584 (England and Wales) 

ONZIMA VENTURES PLC 

ANNUAL REPORT AND FINANCIAL STATEMENTS 

FOR THE YEAR ENDED 31 DECEMBER 2016 

 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

CONTENTS 

Directors and advisers    

               Page 

    1 

Financial highlights and strategic report 

                                3 

Directors report    

                  8 

Corporate governance statement   

Directors’ remuneration report 

Report of the independent auditor 

Consolidated statement of comprehensive income 

Consolidated statement of financial position 

Company statement of financial position 

Consolidated cash flow statement  

Company cash flow statement 

Consolidated statement of changes in equity 

Company statement of changes in equity 

  13 

  15 

  17 

  19  

  20 

  22 

  24 

  25 

  26 

  27 

Notes to the financial statements   

                               28  

 
 
 
 
                                                             
 
 
 
 
 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 
DIRECTORS AND ADVISERS  

Gavin J Burnell 

Luke S Cairns   

Humayun A Mughal 

Page 1 

Chief Executive Officer 

Non-Executive Director 

Non-Executive Director                                                                                          

Lorraine Young Company Secretaries Limited 

Company Secretary 

Registered office 

Website 

Company number 

Auditors 

Accountants 

Solicitors 

6th Floor 
60 Gracechurch Street 
London 
EC3V 0HR 

www.onzimaventures.com 

01435584                                                           

Jeffreys Henry LLP 
Finsgate 
5-7 Cranwood Street 
London 
EC1V 9EE 

Hills Jarrett LLP 
Gainsborough House 
Sheering Lower Road 
Hertfordshire 
CM21 9RG 

Edwin Coe 
2 Stone Buildings 
Lincolns Inn 
London 
WC2A 3TH 

Nominated adviser and broker 

                            Stockdale Securities Limited 

Beaufort House 
15 St Botolph Street 

                                                                                                                London 
                                                                                                                EC3A 7BB 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 
DIRECTORS AND ADVISORS  

Page 2 

Principal bankers 

Registrars 

National Westminster Bank Plc 
PO Box 113, Cavell House 
2a Charing Cross Road                                                               
London 
WC2H 0PD 

Neville Registrars Ltd 
Neville House 
18 Laurel Lane 
Halesowen 
West Midlands 
B63 3DA  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 3 

FINANCIAL HIGHLIGHTS AND STRATEGIC REPORT   
FOR THE YEAR ENDED 31 DECEMBER 2016 

The Directors present their Strategic Report on the Company for the year ended 31 December 2016. 

REVIEW OF THE BUSINESS AND FUTURE DEVELOPMENTS 

Following  the  disposal  of  the  historical  subsidiaries  in  October  2015,  the  Company  commenced  seeking  to 
implement its investing policy. This continued during 2016 when the Company was extremely active, completing in 
excess  of  100  transactions  and  investing  in  19  companies  as  well  as  evaluating  a  number  of  potential  reverse 
takeover opportunities.   

On 1 March 2016, the Company announced that it had acquired 49% of N4 Pharma Limited ("N4 Pharma"), paying 
£41,000 in cash and issuing 24,272,807 new ordinary shares in Onzima. In addition, the Company agreed to provide 
a loan facility of £209,000 to N4 Pharma for the development of its business.  

N4 Pharma is a private company that develops new versions of existing widely used drugs to provide an improved 
patient experience by reformulating its lead product is a novel patentable 'faster acting' version of Viagra which it 
will seek to out-license to a large pharma co-development partner. N4 Pharma has filed for 45 patents. 

N4 Pharma was founded by Nigel Theobald, a successful healthcare entrepreneur with over 25 years' experience in 
the  healthcare  and  biotech  industry.  Nigel  previously  worked  in  senior  positions  at  Alliance  Boots  and  is  former 
CEO  of  Oxford  Pharmascience  Group  Plc  (AIM:OXP).  He  has  a  strong  track  record  in  developing  intellectual 
property into commercial viable opportunities. 

The funds were provided to accelerate the formulation work for N4 Pharma’s novel sildenafil co-crystals (sildenafil 
is  the  generic  drug  name  for  Viagra)  and  undertake  the  initial  proof  of  concept  studies  for  their  faster  acting 
positioning. The erectile dysfunction market had global annual sales of approximately $4.6bn in 2016. Viagra came 
off patent in Europe in 2013 and is still the most widely used drug for erectile dysfunction despite it taking an hour 
before  it  starts  to  work.  A  faster  acting  version  of  Viagra  will  be  a  key  new  player  in  this  attractive  market.  N4 
Pharma also aims to expand its product portfolio and reformulate a wide range of drugs either already off patent or 
coming off patent soon, each of which having an equally attractive commercial opportunity. It was considered that 
N4 Pharma would provide regular news flow for Onzima and its investors. 

As  an  Investing  Company,  the  Company  was  required  to  implement  its  Investing  Policy  within  12  months  of  14 
October  2015  or  make  an  acquisition  or  acquisitions  which  constitute  a  reverse  takeover  under  the  AIM  Rules, 
failing which the Company's ordinary shares would be suspended from trading on AIM.  As at close of business on 
14  October  2016, the  Company  had  not  made  an  acquisition  or  acquisitions  which  constituted  a  reverse takeover 
under  the  AIM  Rules  or  otherwise  implemented  its  Investing  Policy  to  the  satisfaction  of  the  London  Stock 
Exchange.    Accordingly,  in  accordance  with  Rule  15  of  the  AIM  Rules  for  Companies,  the  Company’s  ordinary 
shares were suspended from trading with effect from 7:30 am on 17 October 2016. 

On 17 January 2017, the Company announced that it had agreed in principle terms conditionally to acquire the 51 
per  cent.  of  the  issued  shares  of  N4  Pharma  which  it  did  not  already  own  (the  "Proposed  Acquisition").  The 
consideration  for  the  Proposed  Acquisition  would  be  satisfied  by  the  issue  of  36,409,210  new  ordinary  shares  of 
0.1p  each  in  the  capital  of  Onzima.  It  is  intended  that  at  the  same  time  the  Company  would  seek  to  raise 
approximately £3.0 million by way of a placing of new Ordinary Shares and an open offer to existing shareholders 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 4 

FINANCIAL HIGHLIGHTS AND STRATEGIC REPORT (continued) 

FOR THE YEAR ENDED 31 DECEMBER 2016 

to fund development of additional patented reformulations of a wider range of generic drugs, to undertake clinical 
trials for the Company's reformulation of sildenafil and for working capital purposes. 

The Proposed Acquisition will be classified as a reverse takeover under the AIM Rules and, as a result, is subject to 
the  publication  of  an  admission  document  in  respect  of  the  Company  as  enlarged  by  N4  Pharma  setting  out  full 
details of the Proposed Acquisition and convening a general meeting of the Company where shareholders' approval 
will be sought for, among other things, the Proposed Acquisition and to change the Company's name to N4 Pharma 
plc.  

Onzima is gradually monetising its share portfolio to provide funds  for the  continued development of N4 Pharma 
and the  costs of the Proposed Acquisition.  Following  completion of the Proposed Acquisition, its trading division 
will cease to exist. In January 2017 Onzima also agreed to increase its loan facility to N4 Pharma from £209,000 to 
£309,000. 

In anticipation of the Proposed Acquisition, the Company appointed Stockdale Securities Limited as its nominated 
adviser and broker. 

It is expected that, subject to the completion of satisfactory due diligence, preparation of the requisite documentation 
and  obtaining  shareholders'  approval,  the  Proposed  Acquisition  will  be  completed  in  mid-April  2017 
("Completion").  On  Completion,  it  is  expected  that  new  directors  will  be  appointed  to  the  board  of  Onzima, 
including Nigel Theobald, the founder and Chief Executive of N4 Pharma, and that Professor Mughal and I will step 
down as directors of the Company. 

CHIEF EXECUTIVE OFFICER’S STATEMENT 

The  year  ended  31  December  2016  was  another  transformational  year  for  the  Company.  In  2015  the  historical 
subsidiaries were disposed of and the Company became an Investing Company. 

Simultaneous with the disposals in October 2015 and a fundraising of £750,000 before expenses, Luke Cairns and I 
joined the Board as Directors to seek to implement the investing policy of the Company. 

We sought to immediately be active but selective in our investments and prior to this financial year commencing we 
invested £50,000 in to Glenwick plc which we sold one month later at a 50% profit. 

During  2016  and  prior  to  the  suspension  of  trading  on  AIM  in  the  Company’s  shares  on  17  October  2016  we 
continued to build the investment portfolio in  line with  our investing policy, most notably  with the acquisition of 
49% of N4 Pharma, a very exciting pharmaceutical drug reformulation company. 

We  established  an  asset  trading  division  and  a  business  development  division  in  order  to  separate  our  various 
positions.  The  asset  trading  division  would  focus  on  publicly  traded  investments  and  the  business  development 
division would focus on private opportunities such as N4 Pharma. 

We made numerous exciting investments in to companies within the natural resources sector obtaining equity and in 
some cases warrant positions including Alecto Minerals plc, Ariana Resources plc, Bezant Resources plc, Bushveld 
Minerals Limited, ECR Minerals plc, Ferrum Crescent Limited, Hummingbird Resources plc, Hurricane Energy plc, 
Jubilee  Platinum  plc,  MX  Oil  plc,  Nu-Oil  &  Gas  plc,  Prospex  Oil  &  Gas  plc,  Regency  Mines  plc  and  Savannah 
Resourcesaplc.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 5 

FINANCIAL HIGHLIGHTS AND STRATEGIC REPORT (continued) 

FOR THE YEAR ENDED 31 DECEMBER 2016 

On 17 January 2017, we announced the proposed conditional acquisition of the 51% equity of N4 Pharma that we 
did not already own and the appointment of advisers to assist us with the completion of the transaction which would 
constitute a reverse takeover, a fundraise of approximately £3 million and re-admission to AIM. 

In almost all cases we have now disposed of our listed investments and retain a number of warrant positions that we 
shall seek to monetise in due course where possible. 

We have been pleased with the performance of the Company during the year and are very excited about the future 
prospects for N4 Pharma which could generate very substantial returns for Onzima shareholders. 

FINANCIAL 

During  2016,  the  Company  made  a  loss  from  continuing  operations  of  £22,000  (2015:  loss  of  £151,000).  The 
Company’s  assets  at  31  December  2016  include  investments  of  £302,000  (2015:  £50,000)  and  cash  balances 
amounting to £172,000 (2015: £587,000). 

REVIEW OF THE YEAR 

During 2016 Onzima made investments pursuant to its investing policy utilising the net proceeds of funds raised in 
October 2015 when the Company became an investing company under the AIM Rules. 

The Company was extremely active and completed over 100 transactions prior to October 2016. 

Unfortunately, as the Company had not fulfilled its investing policy under the AIM Rules, trading in the Company’s 
shares was suspended from 17 October 2016. 

The Board was otherwise pleased with the Company’s progress, including the variety of investments made and the 
returns made on its investments, together with the portfolio that it was successfully creating.  

The Board entered negotiations with Nigel Theobald, founder of N4 Pharma, to acquire the remaining 51% of N4 
Pharma.  These  negotiations  were  successful  and  the  Board  is  excited  about  the  future  potential  of  the  group 
assuming completion of the reverse takeover transaction. 

OUTLOOK AND STRATEGY 

Since  the  re-financing  and  disposal  of  the  subsidiaries  the  Company  made  good  progress  with  establishing  its 
portfolio of investments. The Company also sought to maintain a reasonable cash balance for the purpose of making 
new investments. 

Since Onzima was restructured in October 2015, the main focus has been on investing in opportunities within the 
natural resources sector that (provided scope to make significant gains in financing their development.) 

Though  the  sector  remained  difficult  during  early  2016,  the  strategy  has  to  date  been  successful  and  has  yielded 
reasonable returns.  

In  order  to  diversify  the  portfolio,  we  took  a  significant  stake  in  N4  Pharma,  an  early  stage  but  very  exciting 
company  within  the  pharmaceutical  space.  The  market  reacted  well  to  this  position  and  we  have  now  agreed  to 
conditionally buy the other 51% of N4 Pharma to take our holding to 100% ownership. 

We  believe  that  N4  Pharma  represents  a  very  exciting  opportunity  in  a  multibillion-dollar  marketplace.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 6 

FINANCIAL HIGHLIGHTS AND STRATEGIC REPORT (continued) 

FOR THE YEAR ENDED 31 DECEMBER 2016 

Key Developments and Outlook 

In line with the Investing Policy, the Board have been very active and sought suitable investments.  

On  1  March  2016  Onzima  acquired  a  49%  stake  in  N4  Pharma  for  £41,000  cash  together  with  the  issue  of 
24,272,807 new ordinary shares in Onzima alongside the provision of a loan facility to N4 Pharma of £209,000. N4 
Pharma  is  a  private  company  that  develops  new  versions  of  existing  widely  used  drugs  to  provide  an  improved 
patient experience by reformulating them. They continue to make positive progress through potential partners. 

On 17 January 2017, the Company announced that it had agreed in principle terms conditionally to acquire the 51 
per  cent  of  the  issued  shares  of  N4  Pharma  which  it  did  not  already  own.  The  consideration  for  the  Proposed 
Acquisition will be satisfied by the issue of 36,409,210 new ordinary shares of 0.1p each in the capital of Onzima. It 
is intended that at the same time the Company will seek to raise approximately £3.0 million by way of a placing of 
new  Ordinary  Shares  plus  an  open  offer  of  up  to  £1.0  million  to  fund  development  of  additional  patented 
reformulations  of  a  wider  range  of  generic  drugs,  to  undertake  clinical  trials  for  the  Company's  reformulation  of 
Sildenafil and for working capital purposes. 

The Proposed Acquisition will be classified as a reverse takeover under the AIM Rules and, as a result, is subject to 
the  publication  of  an  admission  document  in  respect  of  the  Company  as  enlarged  by  N4  Pharma  setting  out  full 
details of the Proposed Acquisition and convening a general meeting of the Company where shareholders' approval 
will be sought for, among other things, the Proposed Acquisition and to change the Company's name to N4 Pharma 
plc.  

It is the Board’s intention to now complete the Proposed Acquisition. 

Principal risks and uncertainties 

Operational 

The Company presently invests a significant proportion of its available capital in to natural resource companies and 
early stage companies generally. Some of these companies may also be unlisted or illiquid to trade. There is a risk 
that  some  of  these  investments  may  not  produce  a  positive  return  for  the  Company  and  some  of  them  may  fail 
entirely. 

At this stage in its development the Company may be reliant upon raising further funds from investors to support its 
growth. There is no guarantee that these funds will be available to the Company. In addition, there is no guarantee 
that the acquisition of N4 Pharma Limited will complete. 

The principal risks and uncertainties facing the Company relate to the Proposed Acquisition. There is a risk that this 
transaction does not complete. In this event the Company’s shares will be delisted from AIM and the Company may 
not be able to fund its future operations. 

The Group’s financial instruments comprise cash and various items, such as trade receivables and accruals that arise 
directly  from  its  operations.  The  Group’s  exposure  to  its  financial  instruments  is  not  material  and  therefore 
derivative financial instruments are not used to hedge this exposure. 

The main risk arising from the Group’s financial instruments can be analysed as follows:

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 7 

FINANCIAL HIGHLIGHTS AND STRATEGIC REPORT (continued) 

FOR THE YEAR ENDED 31 DECEMBER 2016 

Liquidity risk 

The Group has sufficient cash resources available to meet its short term liabilities. 

The  Company’s  shares  are  currently  suspended  from  trading  on  AIM  and  there  is  no  guarantee  that  they  will  be 
readmitted to trading. 

Interest rate risk 

The Group has no borrowings and receives variable interest based on UK bank base rates on cash balances and bank 
deposits. 

Payment to creditors 

The Group does not follow any code or standard on payment practice and the terms and conditions for its business 
transactions are agreed with individual suppliers. Payment is then made in accordance with those terms, subject to 
the other terms and conditions being met by the supplier. Creditor days at the end of the year for the group were nil 
days (2015: nil days). 

Key Performance Indicators & Financial Performance 

The Board intends to review key performance indicators as the business progresses, at this stage of the Company’s 
life  cycle,  it is  not  yet  able to  measure  key  performance  indicators  in  any  meaningful  way.  The  Board  intends to 
publish key performance indicators in future years. 

At the year end the Company had cash at bank of £172,000 (2015: £587,000). The cash is the primary asset of the 
Company  and  enables  it  to  select  suitable  investments.  As  identified  as  a  risk,  in  time,  further  funding  may  be 
required which with careful and selective investment criteria should be possible to secure. 

Going Concern 

Accounting  standards  require  the  directors  to  consider  the  appropriateness  of  the  going  concern  basis  when 
preparing  the  financial  statements.  The  Directors  confirm  that  they  consider  that the  going  concern  basis remains 
appropriate. The Directors regard the going concern basis as remaining appropriate as the Company and Group have 
adequate  resources  to  continue  in  operational  existence  for  the  foreseeable  future,  coupled  with  experienced 
Directors that are able to seek out additional funding if they believe that it is necessary. 

In closing, the Board would like to extend their thanks to all their shareholders for their continued support and look 
forward to a successful next year. 

………………………………. 

G Burnell 
Chief Executive Officer 

22 March 2017

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

DIRECTORS REPORT  

FOR THE YEAR ENDED 31 DECEMBER 2016 

Page 8 

The directors present their annual report and audited financial statements of Onzima Ventures plc for the year ended 
31 December 2016. 

Business review and principal activities 

The principal activities of the Group during the year were in line with the adoption of the Investing Policy as set out 
below. 

Investing Policy 

The Company will seek to invest a minimum of 75 per cent. of its deployable capital in, and/or acquire companies or 
interests within, the natural resources sector - in which the new Directors have substantial experience as founders, 
investors and advisers. 

The  Company  was  participating  as  an  investor  in  fundraisings  for  entities  being  admitted  to  trading  on  AIM,  in 
secondary fundraisings, or where such entities plan to be admitted to trading on an Exchange within 18 months of 
investment by the Company. 

The Company does not plan to have cross-holdings in entities save where there is a portfolio of related assets outside 
of the Company's control. 

The Board  considers that as investments are made, and new investment opportunities arise, further funding of the 
Company may also be required which is likely to be in the form of equity, until such time as the Company is self-
funding. 

It is intended that returns for Shareholders will initially be in the form of capital growth, subject to appreciation in 
the value of the investments made by the Company. In the longer term, if the Company becomes cash generative, 
then the plan will be to put in place an appropriate dividend policy as appropriate for a Company with its activities at 
that time. 

The Company plans to have a maximum of fifteen investments / interests at any one time. Though there will be no 
maximum exposure to any one investment, it will generally seek to diversify its portfolio holdings. The Company's 
financial resources may ultimately be invested in a number of propositions or in just one investment, which may be 
deemed to be a reverse takeover pursuant to Rule 14 of the AIM Rules requiring shareholder approval. 

The Company also intends to acquire over a period of time a diversified portfolio of royalties. These will consist, in 
varying proportions, of royalties over: 
- producing properties purchased at a discount to perceived value; 
- producing properties with enhanced production possibilities; and 
- non-producing properties where advanced exploration is likely. 

It is intended that over the longer term the royalty investments will provide cash flow to finance further investment 
opportunities,  minimising  dilution  to  Shareholders  through  reduced  equity  financing  requirements.  The  Company 
does not currently intend to fund any investments with debt or other borrowings but may do so if appropriate. The 
Board  may  also  offer  New  Ordinary  Shares  in  the  capital  of  the  Company  by  way  of  consideration  as  well  as 
utilising cash, preserving the Company's cash for additional opportunities and working capital. 

Under  the  Company's  investing  policy,  the  remaining  25  per  cent.  of  the  Company's  deployable  capital  can  be 
invested in to non-natural resource based interests that fit the same criteria as above. 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

DIRECTORS REPORT (continued) 

FOR THE YEAR ENDED 31 DECEMBER 2016 

Directors 

The Directors during the year under review were: 
Gavin Burnell  
Luke Cairns  
Humayun Mughal  

Page 9 

Biographies for each current director can be found on the Company’s website: www.onzimaventures.com. 

Results and dividends 
The Group loss for the year before taxation amounted to £22,000 (2015: loss of £164,000), taxation refund for the 
year of £Nil (2015: £13,000) and a loss after tax of £22,000 (2015: loss of £151,000). Total comprehensive income 
for the year was £(22,000) (2015: £(1,000,000). 

The directors do not recommend the payment of a dividend for 2016. No dividends were paid or proposed in 2015. 

Employees 

The Company does not currently employ any staff. The Directors act for the Company in implementing its Investing 
Policy.                  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 10 

DIRECTORS REPORT (continued) 
FOR THE YEAR ENDED 31 DECEMBER 2016 

Substantial Interests 
At 16 March 2017 the following parties had notified the Company of a beneficial interest that represents 3% or more 
of the Company’s issued ordinary share capital at that date: 

Investing  Nominees 
Limited 

Mr Nigel Theobald 
Hargreaves  Lansdown  (Nominees) 
Limited Des:15942 
Barclayshare Nominees Limited 
TD  Direct 
(Europe) 
Des:SMKTNOMS 
HSDL NOMINEES Limited 
Hargreaves  Lansdown  (Nominees)  
Limited Des:VRA 
HSDL 
Des:SBUILD 
PERSHING  Nominees  Limited 
Des:MDCLT 

Nominees 

Limited 

Number of shares 

      24,272,807  

      12,819,333  
      11,953,194  

      10,740,353  
         9,695,479  

         8,992,588  

         7,869,300  

         6,430,571  

% held 

13.34% 

7.05% 
6.57% 

5.90% 
5.33% 

4.94% 

4.32% 

3.53% 

Directors and Directors’ interest 
The Directors who are currently in office are shown on page 9. The emoluments, share interest and share options of 
the Directors are disclosed in the Directors Remuneration Report on pages 15 to 16. 

Employees 
It is Group policy that employees should be kept as fully informed as is feasible and practicable about the activities 
of  the  Group  through  consultative  meetings.  In  addition,  managers  hold  regular  meetings  with  representatives  of 
their staff in order to encourage employees to make their views known on matters that affect them. 

Pensions 
No contributions were paid in respect of the Directors.

  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 11 

DIRECTORS REPORT (continued) 
FOR THE YEAR ENDED 31 DECEMBER 2016 

Events after reporting date 
On 17 January 2017, the Company announced that it had agreed in principle terms conditionally to acquire the 51% 
on the issued shares of N4 Pharma Limited which it does not already own. The consideration for the acquisition will 
be satisfied by the issue of 36,409,210 new ordinary shares. 

Share Option schemes 
The  Company’s  Microvitec  1994  Inland  Revenue  Approved  Executive  Share  Option  Scheme  approved  by  the 
Company  in the  Annual General  Meeting 1994 has now terminated  (the “Old Scheme”).  There  are no options to 
acquire ordinary shares in the capital of the Company outstanding under the Old Scheme (2013: Nil). 

Ultima Networks Plc 2004 Share Option Scheme 
The scheme was approved by the  AGM  held on 28 May 2004. No options  to subscribe for ordinary shares of 1p 
each have been granted to date. 

Ultima Networks Plc 2012 Share Option Scheme 
The scheme was approved by the AGM held on 26th June 2012. No options to subscribe for ordinary shares of 1p 
each have been granted to date. 

Options were issued to G Burnell and L Cairns. (For further details refer to note 26) 

Charitable and political contributions 
There were no donations to UK charitable organisations (2015: £Nil) and no political donations (2015: £Nil). 

Directors’ responsibilities  
The  directors  are  responsible  for  preparing  the  strategic  report,  directors’  report  and  the  financial  statements  in 
accordance with applicable law and regulations.  

Company  law  requires  the  directors  to  prepare  financial  statements  for  each  financial  year.  Under  that  law  the 
directors  have,  as  required  by  the  AIM  Rules,  elected  to  prepare  the  group  and  company  financial  statements  in 
accordance  with  International  Financial  Reporting  Standards  as  adopted  by  the  European  Union.  Under  company 
law, the directors must not approve the financial statements unless they are satisfied that they  give a true and fair 
view of the state of affairs of the company and the group and of the profit or loss of the group for that period.   In 
preparing these financial statements the directors are required to: 

• 

select suitable accounting policies and then apply them consistently; 

•  make judgments and estimates that are reasonable and prudent; 

• 

• 

• 

state whether the group financial statements have been prepared in accordance with IFRS’s as adopted 
by the European Union; 

state, with regard to the parent company financial statements, whether applicable accounting standards 
have  been  followed,  subject  to  any  material  departures  disclosed  and  explained  in  the  financial 
statements; and  

prepare  the  financial  statements  on  a  going  concern  basis  unless  it  is  inappropriate  to  presume  that  
company and the group will continue in business. 

The  directors  are  responsible  for  keeping  adequate  accounting  records that  are  sufficient  to  show  and  explain  the 
company’s transactions that disclose with reasonable accuracy at any time the financial position of the company and 
the group and enable them to ensure that the financial statements comply with the Companies Act 2006 .They are 
also responsible for safeguarding the assets of the group and hence for taking reasonable steps for the prevention and 
detection 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa

irregularities. 

fraud 

other 

and 

of 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 12 

DIRECTORS REPORT (continued) 
FOR THE YEAR ENDED 31 DECEMBER 2016 

The directors are responsible for the maintenance and integrity of any corporate and financial information included 
on  the  company’s  website.    Legislation  in  the  UK  governing  the  preparation  and  dissemination  of  financial 
statements may differ from legislation in other jurisdictions. 

Statement of disclosure to auditors 

So far as each Director is aware, there is no relevant audit information of which the Company and Group auditors 
are unaware. Additionally, the Directors have taken all the steps that they ought to have taken as Directors in order 
to make themselves aware of any relevant audit information and to establish that the Company and Group auditors 
are aware of the information. 

Annual General Meeting  

The Annual General Meeting of the Company is to be held at 2 Stone Buildings, Lincolns Inn, London WC2A 3TH 
on  Tuesday 18 April 2017 at 10.15am.   

Approval 

The Report of the Directors was approved by the Board on 22 March 2017 and signed on its behalf by 

           ……………………………………….. 

          Gavin Burnell 
          Chief Executive Officer 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 13 

CORPORATE GOVERNANCE STATEMENT 
FOR THE YEAR ENDED 31 DECEMBER 2016 

As a company which shares are admitted to trading on the AIM Market of the London Stock Exchange, the Company is not 
required to comply with the provisions of the 2006 Financial Reporting Council’s revised combined Code. However, the 
Board has sought to commit to ensuring that proper standards of corporate governance operate throughout the Group and 
has  therefore  followed  the  principles  of  the  Code  so  far  as  is  practicable  and  appropriate  to  the  nature  and  size  of  the 
Group. One of the principles is that an explanation should be given where the Code is not complied with. A statement of 
the directors’ responsibilities in respect of the financial statements is contained within the Report of the Directors above. 
The  statement  below  describes  the  role  of  the  Board  and  its  committees,  followed  by  a  statement  regarding  the  groups 
system of internal controls. 

The Board 
The activities of the Group are ultimately controlled by the Board of Directors, which at the  year-end consisted of three 
directors.    Biographical  details  of  all  three  directors  are  available  on  the  Company’s  website.  All  directors  are  equally 
accountable  under law for the proper stewardship of the Company’s affairs. The  Non-executive  director has a  particular 
responsibility to ensure that the strategies proposed by the Executive director are fully discussed and critically examined. 

The  Non-executive  directors  are  Luke  Cairns  and  Humayun  Mughal  and  the  Board  considers  Luke  Cairns  to  be 
independent. 

The Board meets at least four times a year, and more as the need arises. The Board reviews performance of investments, its 
strategy, examines capital expenditure and acquisitions or disposals, operating budgets and material contracts. 

All directors have letters of appointment with the Company.  Any director appointed during the year is required, under the 
Company’s Articles of Association, to retire and seek re-election by the shareholders at the next Annual General Meeting 
and one third of the Board is required to retire each year and seek re-election. The directors are able to take independent 
professional advice at the expense of the company in the furtherance of their duties. 

Nominations committee 
The  appointment  of  directors  is  a  matter for  the  Board  as a  whole  and therefore  a  nominations  committee is  considered 
unnecessary given the present number of Board members. 

Audit committee 
The Audit committee comprises of the two non-executive directors: Luke Cairns and Humayun Mughal. This committee 
assists the Board in its duties regarding the Group’s financial statements and the maintenance of adequate internal financial 
controls. The Audit Committee’s prime tasks are to receive reports from the Company’s auditors, Jeffreys Henry LLP, and 
to review the half-yearly and annual accounts before they are presented to the Board, focusing in particular on accounting 
policies and compliance and areas of management judgements and estimates. 

There is no internal audit function for the Group, as the Board does not believe that this is appropriate given the size of the 
business. 

Remuneration committee 
The Remuneration Committee comprises of the two Non-executive directors Luke Cairns and Humayun Mughal. Details of 
the executive remuneration policy are set out in the separate Directors’ Remuneration Report on pages 15 and 16. 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 14 

CORPORATE GOVERNANCE STATEMENT (continued) 
FOR THE YEAR ENDED 31 DECEMBER 2016 

Shareholder relations 
The Board has a policy of providing any reasonably requested historical information and explanations to shareholders on 
request. The Group’s annual reports are sent to shareholders. These reports are also available from the company’s website 
along with the Group’s half yearly reports and all public announcements. All shareholders are encouraged to participate in 
the company’s Annual General Meeting, which is attended by the directors.  

Internal control and financial reporting 
The  Board  is  responsible  for  ensuring  that  there  is  a  system  of  internal  control  for  reviewing  its  effectiveness.  Such  a 
system is designed to manage rather than eliminate the risk of failure to achieve business objectives and can only provide 
reasonable  and  not  absolute  assurance  against  material  misstatement  or  loss.  The  Audit  Committee  has  been  delegated 
responsibility by the Board for discharging its internal control responsibilities. 

The  Board  has  established  an  organisational  structure  with  clearly  defined  levels  of  responsibility  and  delegation  of 
authority. Control procedures include annual budget approval and monitoring of actual performance. The Board approves 
all investment and acquisition projects for all major acquisitions and major capital expenditure.  

The Board has a clear responsibility for identifying risks facing each of the businesses and for putting in place procedures 
to mitigate and monitor risks. As part of the annual budgeting process risks are formally assessed by the Board. 

There is a system of financial reporting and budget planning. On a monthly basis, actual results are reported and compared 
to budget with any significant adverse variances being examined and any remedial action taken as necessary. 

The  directors  believe  that, taken  as  a  whole,  the systems of  internal  control  are  appropriate  to  the  business  for the  year 
ended 31 December 2016. 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 15 

DIRECTORS’ REMUNERATION REPORT 

FOR THE YEAR ENDED 31 DECEMBER 2016 

The directors present the Directors remuneration report for the year ended 31 December 2016. It should be noted that, as a 
company  quoted  on  the  AIM  market  of  the  London  Stock  Exchange,  the  company  is  not  required  to  comply  with  the 
Remuneration Report regulations and therefore, not all elements of the regulations have been complied with. For example, 
a share price graph has been omitted.  

Remuneration committee 
The Remuneration committee consists of Non-executive directors Luke Cairns and Humayun Mughal.  

The Remuneration committee determines any remuneration and benefits packages of the executive directors and considers 
any service contracts, salaries, other benefits, including bonuses and participation in the company’s share option plans, and 
any other terms and conditions of employment including any compensation payments on termination of office. 

Remuneration policy 
Any  basic  salaries  and  benefits  in  kind  are  set  to  be  comparable  with  those  of  peer  group  companies.  The  Company 
operates historic share schemes but these do not form part of the current remuneration policy. It is planned to put in place a 
formal share option scheme in due course. 

Non-executive directors 
The Non-executive directors do not have a contract for services. The Non-executive directors have letters of appointment 
concerning, amongst other things, the initial terms for which he was appointed, a general statement of their role and duties, 
the fees they will receive as a director and any supplementary fees receivable for additional work, such as being a member 
of more than one Board committee.  The fees of Non-executive directors are determined by the full Board within the limits 
set out in the Memorandum and Articles of Association. 

Service contracts and letters of appointment 

The company does not have service contracts in respect of the Executive Directors. The letters of appointment in respect of 
the  Non-executive  directors who  served during the  year ended 31 December 2016 is for a  rolling 12-month period. The 
letters of appointment contain notice periods for non-executive directors of 1 month executive directors of 6 months and no 
provision for termination payments.  

Directors’ remuneration and interests 

Directors’ remuneration payable for the year ended 31 December 2016 was as follows: 

Executive 
H A Mughal 
A P Klein 
G Burnell 

Non-Executive 
H A Mughal 
L Cairns 

Basic  

Salary 
£000 

- 
- 
43 

- 
15 

58 

Benefits 

in kind 
£000 

- 
- 
- 

- 
- 

- 

Fees 
£000 

- 
- 
- 

15 
- 

15 

Share based 
payments 
Total £000  Total £000  Total £000 

2016 

2015  

- 
- 
- 

- 
- 

- 

- 
- 
43 

15 
15 

73 

45 
9 
25 

- 
6 

85 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 16 

DIRECTORS’ REMUNERATION REPORT (continued) 
FOR THE YEAR ENDED 31 DECEMBER 2016 

The  beneficial  interest  in  the  share  capital  of  the  Company  of  those  persons,  who  were  directors  at  the  year  end,  as 
recorded in the register of the Directors’ interest, were as follows: 

H A Mughal 
G Burnell 
L Cairns 

31 December 2016 

Ordinary 
shares of 1p 

Ordinary 
share options 

11,232,517 
3,571,428 
- 

- 
10,804,840 
2,701,210 

31 December 2015 

Ordinary 
shares of 1p 

Ordinary 
share options 

11,232,517 
3,571,428 
- 

- 
10,804,840 
2,701,210 

Gavin Burnell and Luke Cairns directors of the Company were granted share options over 10,804,840 and 2,701,210 shares 
respectively on 14 October 2015. No director has granted or exercised any share options during this or the previous year 
nor did any lapse.    

Directors’ remuneration and interests  

Beneficial holdings include the directors’ personal holdings and those of their spouse and children as well as holdings in 
family trusts of which the directors’ spouse or their children are beneficiaries or potential beneficiaries. 

The closing mid-market price at 16 October 2016 when the ordinary shares were suspended from trading was 1.25p and the 
range during the year was 1.95p to 0.425p. 

Approval 

The Directors’ Remuneration Report was approved by the Board on 22 March 2017 and signed on its behalf by: 

………………………………………………………. 

Gavin Burnell 
Chief Executive Officer 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                   
ONZIMA VENTURES PLC                                                                                                                                     Page 17  

INDEPENDENT AUDITORS’ REPORT 

INDEPENDENT AUDITORS’ REPORT TO THE MEMBERS OF ONZIMA VENTURES PLC 

We have audited the financial statements of Onzima Ventures Plc for the year ended 31 December 2016, which comprise 
the Consolidated Statement of Comprehensive Income, Consolidated Statement of Changes in Equity, Company Statement 
of  Changes  in  Equity,  Consolidated  Statement  of  Financial  Position,  Company  Statement  of  Financial  Position, 
Consolidated Statement of Cash Flows, Company Statement of Cash Flows and the related notes on pages 19 to 52. The 
financial  reporting  framework  that  has  been  applied  in  their  preparation  is  applicable  law  and  International  Financial 
Reporting Standards (IFRSs) as adopted by the European Union and as regards the parent company financial statements as 
applied in accordance with the provisions of the Companies Act 2006. .  

This  report  is  made  solely  to  the  Company's  members,  as  a  body,  in  accordance  with  Chapter  3  of  Part  16  of  the 
Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters 
we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we 
do not accept or assume responsibility to anyone other than the Company and the Company's members as a body, for our 
audit work, for this report, or for the opinions we have formed. 

Respective responsibilities of directors and auditors 
As explained more fully in the Statement of Directors' Responsibilities set out on page 11, the directors are responsible for 
the preparation of the financial statements and for being satisfied that they give a true and fair view. Our responsibility is to 
audit the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). 
Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors. 

Scope of the audit of the financial statements 
An  audit  involves  obtaining  evidence  about  the  amounts  and  disclosures  in  the  financial  statements  sufficient  to  give 
reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. 
This  includes  an  assessment  of:  whether  the  accounting  policies  are  appropriate  to  the  Group’s  and  Parent  Company's 
circumstances  and have been consistently applied and adequately disclosed; the reasonableness  of significant accounting 
estimates  made  by  the  directors;  and  the  overall  presentation  of  the  financial  statements.  In  addition  we  read  all  the 
financial and non-financial information in the Financial Highlights and Strategic Report and Directors’ Report to identify 
material inconsistencies with the audited financial statements and to identify any information that is apparently materially 
incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If 
we become aware of any apparent material misstatement or inconsistencies we consider the implications for our report. 

Opinion on financial statements 

In our opinion: 

• 

• 

• 

• 

the  financial statements give a true and fair view of the state of the group’s  and  of the parent company’s  state of 
affairs as at 31 December 2016 and of the group’s loss and the group’s and parent company’s cash flow for the year 
then ended; 
the group financial statements have been properly prepared in accordance with IFRS’s as adopted by the European 
Union;  
the parent company financial statements have been properly prepared in accordance with IFRS’s as adopted by the 
European Union and as applied in accordance with the provisions of the Companies Act 2006; and  
the financial statements have been prepared in accordance with the provisions of the Companies Act 2006.                                      

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                      
 
 
 
ONZIMA VENTURES PLC 
INDEPENDENT AUDITORS’ REPORT (continued…) 

                             Page 18 

Opinion on other matters prescribed by the Companies Act 2006 

In our opinion the information given in the Strategic Report and Directors’ Report for the financial year for which 
the financial statements are prepared is consistent with the financial statements. 

Matters on which we are required to report by exception 

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to 
you if, in our opinion:  

adequate accounting records have not been kept by the parent company, or returns adequate for our audit        

- 
………..have not been received from branches not visited by us; or    
- 
- 
- 

the parent company financial statements are not in agreement with the accounting records and returns; or  
certain disclosures of directors' remuneration specified by law are not made; or  
we have not received all the information and explanations we require for our audit. 

Sachin Ramaiya (Senior Statutory Auditor) 

For and on behalf of Jeffreys Henry LLP, statutory auditor  

Finsgate 
5-7 Cranwood Street 
London 
EC1V 9EE 
United Kingdom 

Date: 22 March 2017 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 19 

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME 
AS AT 31 DECEMBER 2016 

Revenue 

Cost of sales 

Gross profit 

Administration expenses 

Operating loss 

Finance income/(expenditure) 

Loss before taxation 

Taxation recovery 

Loss for the year from continuing operations 

Discontinued operations 

Loss for the year from discontinued operations 

Loss for the year 

Other comprehensive income: 
Exchange difference on translating foreign operations 
Total comprehensive income for the year attributable to 
equity holders of the parent 

Note 

5 

8 

10 

6 

2016 
£000 

1,155) 

(934) 

221) 

(249) 

(28) 

6) 

(22) 

-) 

(22) 

(-) 

(22) 

-) 

2015 
£000 

-))) 

  (- 

-))) 

    (160) 

    (160) 

(4)) 

(164)) 

13)) 

(151)) 

(902) 

(1,053) 

53) 

     (22) 

(1,000) 

Basic and diluted loss per share – pence 

11 

(0.02) 

(2.27) 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 20 

CONSOLIDATED STATEMENT OF FINANCIAL POSITION 
AS AT 31 DECEMBER 2016 

ASSETS 
Non current assets 
Investments 
Other receivables 

Total non current assets 

Current assets 
Inventory of securities 
Trade and other receivables 
Cash and cash equivalents 

Total current assets 

Total assets 

LIABILITIES 
Current liabilities 
Trade and other payables 
Current tax liabilities 
Accruals and deferred income 

Total current liabilities 

Total liabilities 

Net assets 

Note 

13 
17 

16 
17 
18 

19 
10 

2016 
£000 

302 
215 

517 

232 
197 
172 

601 

1,118 

-) 
-) 
(77) 

(77) 

(77) 

1,041 

2015 
£000 

50 
- 

50 

- 
21 
587 

608 

658 

-) 
-) 
(17) 

(17) 

(17) 

641 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 21 

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (continued) 
AS AT 31 DECEMBER 2016 

EQUITY 
Capital and reserves attributable to equity holders of the 
parent 
Called up share capital 
Share premium account 
Other reserves 
Share option reserve 
Retained Earnings 

  Note 

22 

2016 
£000 

2015 
£000 

8,453) 
6,881) 
-)) 
                  31) 
           (14,324) 

8,409) 
6,503) 
-)) 
                  31) 
           (14,302) 

1,041) 

641) 

These financial statements were approved and authorised for issue by the board of directors on 22 March 2017 and were 
signed on its behalf by: 

........................................................................ 
Gavin Burnell 
Chief Executive Officer 

Company Registration Number 01435584 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 22 

COMPANY STATEMENT OF FINANCIAL POSITION 
AS AT 31 DECEMBER 2016 

ASSETS 
Non current assets 
Investments 
Other receivables 

Total non current assets 

Current assets 
Inventory of securities 
Trade and other receivables 
Cash and cash equivalents 

Total current assets 

Total assets 

LIABILITIES 
Current liabilities 
Trade and other payables 
Current tax liabilities 
Accruals and deferred income 

Total current liabilities 

Total liabilities 

Net assets 

Note 

13 
17 

16 
17 
18 

19 
10 

2016 
£000 

302 
215 

517 

232 
197 
172 

601 

1,118 

- 
- 
(77) 

(77) 

(77) 

1,041 

2015 
£000 

50 
- 

50 

- 
21 
587 

608 

658 

- 
- 
(17) 

(17) 

(17) 

641 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 23 

COMPANY STATEMENT OF FINANCIAL POSITION (continued) 
AS AT 31 DECEMBER 2016 

EQUITY 
Capital and reserves attributable to equity holders of the 
parent 
Called up share capital 
Share premium account 
Other reserves 
Share option reserve 
Retained Earnings 

Note 

22 

2016) 
£000) 

2015) 
£000) 

8,453) 
6,881) 
-) 
                  31) 
(14,324) 

8409) 
6,503) 
-) 
                  31) 
(14,302) 

1,041) 

641) 

These financial statements were approved and authorised for issue by the board of directors on 22 March 2017 and were 
signed on its behalf by: 

........................................................................ 
Gavin Burnell 
Chief Executive Officer 

Company Registration Number 01435584 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 24 

CONSOLIDATED CASH FLOW STATEMENT 
FOR THE YEAR ENDED 31 DECEMBER 2016 

Loss for the financial year 
Taxation recoverable 
Interest  
Comprehensive income 
Movement in reserves 
Depreciation charges 
Amortisation of intangibles 

Operating loss  before changes in working capital 

Decrease/(Increase) in inventories 
Decrease/(Increase) in trade and other receivables 
(Decrease)/increase in trade payables and other capital liabilities 

Cash (used in)/generated from operations 

Taxation 

Net cash (used in)/generated from operating activities 

Cash flows from investing activities 
Movement in property, plant and equipment 
Movement in investments 
Decrease/(Increase) in other receivables 
Net proceeds of ordinary shares issue 

Net cash used in investing activities 

Cash flows from financing activities 
Interest received 

Net cash generated from financing activities 

Net (decrease)/increase in cash and cash equivalents 

Cash and cash equivalents at beginning of the period 

Cash and cash equivalents at end of the period 

2016) 
£000) 

(22) 
-) 
(6) 
-) 
-) 
-) 
-) 

(28) 

(  (232) 
(  (176) 
60) 

(376) 

-)  

(376) 

-) 
(9) 
(  (209) 
179) 

(39) 

-) 

-) 

(415) 

587) 

172) 

2015) 
£000) 

(1,053) 
 (13) 
4) 
53) 
(171) 
230) 
-) 

(950) 

(  347) 
(  518) 
(790) 

(875) 

13)  

(862) 

386) 
(50) 
-) 
770) 

1,106) 

(4) 

(4) 

240) 

347) 

587) 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 25 

COMPANY CASH FLOW STATEMENT 
FOR THE YEAR ENDED 31 DECEMBER 2016 

Loss for the financial year 
Interest payable 
Disposal of investments 
Movement in reserves 
Depreciation charges 

Operating loss  before changes in working capital 

(Increase)/decrease  in inventories 
(Increase)/decrease  in trade and other receivables 
(Decrease)/increase in trade payables and other current 
liabilities 

Cash (used in)/generated from operations 

Taxation 

Net cash (used in)/generated from operating activities 

Cash flows from investing activities 
Movement in investments 
Decrease/(Increase) in other receivables 
Net costs of ordinary shares issue 
Purchase of property, plant and equipment 

Net cash used in investing activities 

Net (decrease)/increase in cash and cash equivalents 

Cash and cash equivalents at beginning of the period 

Cash and cash equivalents at end of the period 

2016) 
£000) 

(22) 
(6) 
-) 
-) 
-) 

(28) 

(232) 
(176) 
60) 

 (376) 

-)) 

 (376) 

(9) 
(  (209) 
179) 
-) 

(39) 

 (415) 

587) 

172) 

2015) 
£000) 

(382) 
-) 
292) 
(171) 
232) 

(29) 

44) 
1,838) 
 (2,247) 

 (394) 

-)) 

 (394) 

(50) 
-) 
770) 
112) 

832) 

 438) 

149) 

587) 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 
FOR THE YEAR ENDED 31 DECEMBER 2016 

Page 26 

GROUP 

Called 
up share  
capital 

Share 
premium 

Other 
reserves 

Share 
option 
reserve 

Retained 
earnings 

Translation 
of foreign 
operations 

Total  
Equity 

) 

£000 

£000 

£000 

£000 

£000 

£000 

£000 

Year ended 31 December 2016 
As 1 January 2016 
Share issue 
Movement in reserves 
Share option reserve 
Total comprehensive income for 
the year 

8,409 
44) 
-) 
-) 

6,503 
378 
-) 
-) 

- 

- 

At 31 December 2016 

8,453 

6,881 

Year ended 31 December 2015 
As 1 January 2015 
Share issue 
Movement in reserves 
Share option reserve 
Total comprehensive income for 
the year 

8,299 
110) 
-) 
-) 

5,843 
660 
-) 
-) 

- 

- 

At 31 December 2015 

8,409 

6,503 

-) 
-) 
-) 
-) 

- 

-) 

202 
-) 
(202) 
-) 

- 

-) 

31 
- 
- 
- 

(14,302) 
-) 
-) 
-) 

(22) 

31 

(14,324) 

- 
- 
- 
31 

(13,249) 
-) 
-) 
-) 

-) 
-) 
-) 
-) 

- 

-) 

(53) 
-) 
-) 
-) 

641) 
422) 
-) 
-) 

(22) 

1,041) 

1,042) 
770) 
(202) 
31 

(1,053) 

53) 

(1,000) 

31 

(14,302) 

-) 

641) 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 27 

COMPANY STATEMENT OF CHANGES IN EQUITY 
FOR THE YEAR ENDED 31 DECEMBER 2016 

COMPANY 

Called 
up share  
capital 

Share 
premium 

Other 
reserves 

Share 
option 
reserve 

Retained 
earnings 

Total  
Equity 

) 

£000 

£000 

£000 

£000 

£000 

£000 

Year ended 31 December 2016 
As 1 January 2016 
Share issue 
Movement in reserves 
Share option reserve 
Profit for the period 

8,409 
44) 
-) 
-) 

6,503 
378 
-) 
-) 

- 

- 

At 31 December 2016 

8,453 

6,881 

-) 
-) 
-) 
-) 

- 

-) 

31 
- 
- 
- 

(14,302) 
-) 
-) 
-) 

(22) 

641) 
422) 
-) 
-) 

(22) 

31 

(14,324) 

1,041) 

Year ended 31 December 2015 
As 1 January 2015 
Share issue 
Movement in reserves 
Share option reserve 
Profit for the period 

8,299 
110) 
-) 
-) 
-) 

5,843 
660 
-) 
-) 
-) 

202 
-) 
(202) 
-) 
-) 

- 
- 
- 
31 
- 

(13,920) 
-) 
-) 
-) 
(382) 

At 31 December 2015 

8,409 

6,503 

-) 

31 

(14,302) 

424) 
770) 
(202) 
31 
(382) 

641) 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 28 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

1.  GENERAL INFORMATION 

In the prior year Onzima Ventures Plc (“the Company”) and its subsidiaries (together “the Group”) were involved in 
the marketing and support of computer application software and the merchandising of various products, but primarily 
electric bicycles. The company sold the subsidiaries on 14 October 2015 and operates now as an investment holding 
company.  

The  company  is  a  public  limited  company,  which  is  quoted  on  the  AIM  of  The  London  Stock  Exchange  and  is 
incorporated  and  domiciled  in  the  United  Kingdom.  The  address  of  its  registered  office  is  6th  Floor,  Gracechurch 
Street, London, EC3V 0HR. 

The Group’s and company’s financial statements for the year ended 31 December 2016, were authorised for issue by 
the Board of Directors on 22 March 2017 and the balance sheets were signed on the Boards behalf by Gavin Burnell.  

2.  ACCOUNTING POLICIES 

The  principal  accounting  policies  applied  in  the  preparation  of  these  financial  statements  are  set  out  below.  These 
policies have been applied consistently to all years presented, unless otherwise stated.  

Basis of preparation 
These financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) 
and the interpretations of the International Financial Reporting Interpretations Committee (IFRIC) as adopted by the 
European Union, and with those parts of the Companies Act 2006 applicable to companies reporting under IFRS. 

These  financial  statements  have  been  prepared  on  the  historic  cost  basis  except  where  financial  instruments  are 
required to be carried at fair value under IFRS. 

The financial statements are presented in pounds sterling, being the functional currency of the parent and all values are 
rounded to the nearest thousand pounds (£000) except where otherwise indicated. 

Going concern 

Having  reviewed  the future plans  and  projections  for  the  business, the  directors  are  satisfied that the  Company  and 
Group have adequate resources to continue to operate for the foreseeable future, a period not less than twelve months 
from  the  date  of  approval  of  the  financial  statements.  This  will  also  depend  on  the  continuing  support  from  the 
shareholders and directors. For these reasons, the directors continue to adopt the going concern basis in preparing the 
financial statements. 

Were  the  group  and  company  unable  to  continue  as  a  going  concern,  adjustments  would  have  to  be  made  to  the 
statement of financial position of the group and company to reduce the value of assets to their recoverable amounts, to 
provide  for  future  liabilities that  might  arise  and  to  reclassify  non-current  assets  and  long-term  liabilities  as  current 
assets and liabilities. 

Basis of consolidation  
The consolidated financial statements incorporate the results and net assets of Onzima Ventures Plc and its subsidiary 
undertakings (together referred to as “the Group”) for the year ended 31 December 2016. A subsidiary is an entity over 
which the Group has the power to govern the financial and operating policies generally accompanying a shareholding 
of more than 50% of the voting rights. The results of each subsidiary are included from the date that control transferred 
to the group and are  adjusted to align  accounting policies with  the Group’s accounting  policies. Subsidiaries  are no 
longer  consolidated  from  the  date  that  control  ceases.  Unrealised  gains  on  transactions  between  the  group  and  its 
subsidiaries  are  eliminated  and  unrealised  losses  are  also  eliminated  unless  the  transaction  provides  evidence  of  an 
impairment  of  the  asset  transferred.  All  intercompany  balances  and  transactions  are  eliminated  in  full.  Amounts 
reported in the financial statements of subsidiaries have been adjusted where necessary to ensure consistency with the 
accounting policies adopted by the group.  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 29 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

2.  ACCOUNTING POLICIES (continued) 

Company investment in subsidiaries 
In  its  separate  financial  statements,  the  company  recognises  its  investments  in  subsidiaries  at  cost.  Income  is 
recognised from these investments only in relation to distributions received from post acquisition profits. 

Share-based payments 
For equity settled share based payment transactions the Group, in accordance with IFRS 2 “Share Based Payments” 
measures their value, and the corresponding increase in equity, indirectly, by reference to the fair value of the equity 
instruments granted. The fair value of those equity instruments is measured at the grant date using the Black-Scholes 
method. The expense is  apportioned over the vesting period of  the financial instrument and is based on the number 
which is expected to vest and the fair value of those financial instruments at the date of grant. If the equity instruments 
granted vested immediately, the expense is recognised in full. 

Other intangible assets 
Other intangible assets include technology platform and customer relationships. These are only recognised if acquired 
in a business combination. They are stated at fair value less accumulated amortisation. These assets are amortised over 
their estimated useful lives of 10 years and the charge is included in administration expenses. 

Revenue recognition  
Revenue is recognised at the point of sale of the investments. 

Segment reporting 
A business segment is a group of assets and operations engaged in providing products or services that are subject to 
risks and returns that are different from those of other business segments and whose operating results are reviewed on 
a regular basis by the Group’s board and for which discrete financial information is available. A geographical segment 
is  engaged  in  providing  products  or  services  within  a  particular  economic  environment  that  is  subject  to  risks  and 
environments. 
returns 

segments  operating 

are  different 

those  of 

in  other 

economic 

form 

that 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 30 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

2.  ACCOUNTING POLICIES (continued) 

Property, plant and equipment 
Property, plant and equipment is carried at cost less accumulated depreciation and any recognised impairment in value. 
Cost comprises the aggregate amount paid to acquire the asset and includes costs directly  attributable to making the 
asset capable of operating as intended. 

All land and buildings are included at valuation. Valuations are kept up-to-date through periodic valuations carried out 
by external valuers.  

Depreciation is provided evenly on the cost (or valuation where appropriate) of the assets, to write them down to their 
estimated residual values over their expected useful lives. No depreciation is provided on freehold land. The principal 
annual rates used for the other assets are:  

Freehold buildings   
Office equipment 
Motor vans 
Computer equipment 

- 25 to 50 years 
- 3 to 5 years 
- 4 years 
- 3 years 

The assets’ residual values, useful lives and methods of depreciation are reviewed, and adjusted, if appropriate, on an 
annual  basis.  An item  of  property,  plant  and  equipment  is  derecognised  upon  disposal or  when  no  future  economic 
benefits are expected from its use or disposal. A gain or loss arising on derecognition of the asset (calculated as the 
difference between the net disposal proceeds and the carrying amount of the asset) is included in the income statement 
in the year that the asset is derecognised.  

Impairment of assets 
At  each  balance  sheet  date,  the  Group  reviews  the  carrying  amounts  of  its  property,  plant  and  equipment  and 
intangible assets to determine whether there is any indication that these assets have suffered an impairment loss. If any 
such indication exists, the recoverable amount of the asset, which is the higher of its fair value less costs to sell and its 
value in use, is estimated in order to determine the extent of the impairment loss. Where the asset does not generate 
cash flows that are independent from other assets, the Group estimates the recoverable amount of the cash-generating 
unit to which the asset belongs. 

An  impairment  charge  is  recognised  in  the  income  statement  in  the  year  in  which  it  occurs.  With  the  exception  of 
goodwill, all assets are subsequently reassessed for indications that an impairment loss previously recognised may no 
longer  exist.  The  carrying  amount  of  the  asset  is  increased  to  the  revised  estimate  of  its  recoverable  amount.  The 
increased  amount  cannot  exceed  the  carrying  amount  that would  have  been  determined,  net  of  depreciation,  had  no 
impairment loss been recognised for the asset in prior years.   

Inventories 
Inventories are investments and valued at the lower of cost and net realisable value. In the prior year to 14 October 
2015 cost of raw materials, consumables and goods purchased for resale means actual price, including transport and 
handling and is determined using FIFO method. Net realisable value means estimated net selling price less estimated 
costs of disposal.  

Trade and other receivables 
Trade receivables are recognised initially stated at fair value and subsequently measured at amortised cost using the 
effective  interest rate  method.  Provision  against  trade  receivables  is  made  when there is  objective  evidence  that the 
Group will not be able to collect all amounts due to it in accordance with the original terms of those receivables. The 
amount of the write-down is determined as the difference between the asset’s carrying amount and the present value of 
estimatedafutureacashaflows.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 31 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

2.  ACCOUNTING POLICIES (continued) 

Cash and cash equivalents 
Cash  and  cash  equivalents  includes  cash  in  hand,  deposits  held  at  call  with  banks,  other  short-term  highly  liquid 
investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within 
financial liabilities in current liabilities on the balance sheet. 

Trade and other payables 
Trade payables are not interest bearing  and  are initially  stated  at their fair value and then subsequently measured  at 
amortised cost using the effective interest method.  

Income taxes 
Current income tax assets and liabilities are measured at the amount expected to be recovered or paid to the taxation 
authorities, based on tax rates and laws that are enacted or substantively enacted by the balance sheet date. 

Deferred income tax is recognised using balance sheet liability method, providing for temporary differences between 
the tax bases and the accounting bases of assets and liabilities. Deferred income tax is calculated on an undiscounted 
basis at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised, based 
on tax rates and law enacted or substantively enacted at the balance sheet date.  

Deferred  income  tax  liabilities  are  recognised  for  all  temporary  differences,  except  when  deferred  income  tax 
liabilities  arise from the initial recognition  of  goodwill or  an  asset  or liability  in  a transaction that is  not  a  business 
combination and at the time of transaction, affects neither the accounting profit nor taxable profit or loss.  

Deferred income tax is charged or credited to the income statement, except when it relates to items charged or credited 
directly to equity, in which case the deferred tax is also dealt with in equity. Deferred income tax assets and liabilities 
are offset against each other only when the Group has a legal enforceable right to do so. 

Deferred  income  tax  assets  are  recognised  only  to  the  extent  that  it  is  probable  that  future  taxable  profits  will  be 
available against which the deductible temporary differences can be utilised.  

Pensions 
The  Group  does  not  operate  any  pension  schemes,  but  does  contribute  to  the  personal  pension  schemes  (defined 
contribution) of certain staff. The contributions are charged as an expense as they fall due. Any contributions unpaid at 
the balance sheet date are included as an accrual at that date. The Group has no future payment obligations once the 
contributions have been paid.    

Leased assets – Group as lessee 
Leases are classified as finance leases when the terms of the lease transfer substantially all the risks and rewards of 
ownership to the Group. All other leases are classified as operating leases. 

Assets leased under operating leases are not recorded on the balance sheet. Rentals payable are charged direct to the 
income  statement.  Lease  incentives,  for  example,  up-front  cash  payments  or  rent  free  periods,  are  capitalised  and 
spread  over  the  period  of  the  leased  term.  Payments  made  to  acquire  operating  leases  are  treated  as  prepaid  lease 
expenses and amortised over the useful life of the lease.  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 32 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

2.  ACCOUNTING POLICIES (continued) 

Leased asset - Group as lessor 
Assets  leased  out  under  operating  leases  are  included  in  property,  plant  and  equipment  and  depreciated  over  their 
useful lives. Rental income, including the effect of lease incentives, is recognised on a straight line basis over the lease 
term.  

Components of equity 
Equity comprises the following: 

•  Share capital represents the nominal value of equity shares, 
•  Share  premium  represents  the  excess  over  nominal  value  of  the  fair  value  of  consideration  received  for 

equity shares, net of expenses of the share issue,  

•  Other  reserves  represents  Merger  Reserve  and  represents  the  difference  between  the  value  of  the  shares 
acquired  and  the  nominal  value  where  the  shares  have  been  issued  as  part  of  the  consideration  for 
acquisitions, and 

•  Share options reserves relate to the charge for the share based payment in accordance with IFRS 2. 
•  Profit and loss reserve represents retained profits. 

Use of assumptions and estimates 
The Group makes judgements, estimates and assumptions that affect the application of policies and reported amounts 
of assets and liabilities, income  and  expenses. The resulting accounting estimates calculated using these judgements 
and assumptions will, by definition, seldom equal the related actual results but are based on historical experience and 
expectations of future events. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions 
to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that 
period, or in the period of revisions and future periods if the revision affects both current and future periods.  

The estimates and assumptions that have a significant effect on the amounts recognised in the financial statements are: 

•  Estimates in relation to future cash flows and discount rates utilised in impairment testing, 
•  Management intentions for realisation of tax assets and liabilities under IAS 12. 
•  Cash flow forecasts relating to the impairment review of the investment in N4 Pharma. 

STATEMENT OF COMPLIANCE 

Issued International Financial Reporting Standards (IFRS) and Interpretations Committee (IFRIC) relevant 
to the Group Operations 
There are no IFRS or IFRIC interpretations that are effective for the first time in this financial period that would be 
expected to have a material impact on the Company. 

Standards, interpretations and amendments to published standards that are not yet effective 
There are no other IFRS and IFRIC interpretations that are not yet effective that would be expected to have a 
material impacts on the company. 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 33 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

3.  SEGMENTAL REPORTING 

The Group operated in the United Kingdom, Italy and Spain until its subsidiaries sold on 14 October 2015. 
Prior to disposal, the Group was organised into two principal business segments: 

• 

IT and related services (comprising legal and publishing application software)  

•  Green  technology  (comprising  electric  bicycles,  energy  saving  lamps,  educational  electronic  kits  and 

development of solar power parks) 

The company now operates as an investment holding company. 

The segmental results for the year ended 31 December 2016 are as follows:  

Investment 
Holding 
UK 
£000 

1,155 

- 

- 

- 

(22) 

Unallocated 

Company 

£000 

- 

- 

- 

- 

-) 

£000 

1,155 

- 

- 

- 

(22) 

Revenue 

Depreciation 

Amortisation 

Interest payable 

Operating profit/(loss) 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 34 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

3.  SEGMENTAL REPORTING (continued) 

The segmental results for the year ended 31 December 2015 were as follows: 

IT and related 
services 
UK 
£000 

Green 
technology 
UK 
£000 

Revenue 

579 

311 

Depreciation 

Amortisation 

Interest payable 

- 

- 

- 

- 

- 

4 

Operating profit/(loss) 

(20) 

(140)) 

2016 

Segment assets 
Segment liabilities 

Net assets 

Investment 
Holding 
UK 
£000) 

1,118) 
(77) 

1,041) 

Unallocated 

Group 

£000 

- 

230 

- 

- 

-) 

£000 

890 

230 

- 

4 

(160) 

Unallocated 

Company 

£000) 

£000) 

-) 
-) 

-) 

1,118) 
(77) 

1,041) 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 35 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

3.  SEGMENTAL REPORTING (continued) 

The other information of the segments was as follows:  

2015 

Segment assets 
Segment liabilities 

Net assets 

IT and related) 
services) 
UK) 
£000) 

Green) 
technology) 
UK) 
£000) 

Unallocated) 

Group) 

£000) 

£000) 

-) 
-) 

-) 

-) 
-) 

-) 

658) 
(17) 

641) 

658) 
(17) 

641) 

4.  PRESENTATIONAL ADJSTMENTS 

The prior  year results have been presented to reflect the discontinued operation in 2015. Refer to note 6 for more 
details. 

5.  OPERATING PROFIT 

Operating profit is stated after charging: 
Depreciation plant and equipment 
Amortisation of intangible assets 
Operating leases – rent of building 

2016 
£000 

-) 
-) 
-) 

2015 
£000 

230 
-) 
43 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 36 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

6.  DISCONTINUED OPERATIONS 

On  the  25  September  2015  the  group  entered  into  a  sale  agreement  to  dispose  of  Cognito  Software  Solutions 
Limited, UTN Solutions (North) Limited and Tre-Sol Italia srl, which carried out all of the group’s operations. The 
disposal was completed on 14 October 2015 on which date control passed to the acquirer. 

The results of the discontinued operations, which have been included in the consolidated income statement, were as 
follows: 

Revenue 
Expenses 
Loss before tax 
Loss on disposal of discontinued operations 
Net loss attributable to discontinued operations (attributable 
to owner of the Company) 

7.  AUDITORS REMUNERATION 

 Services provided by the Company’s auditor and its associates 

Group 
Fees payable to the company’s auditor for the audit of the 
company and consolidated financial statements 

8.  FINANCE INCOME & EXPENSE 

Finance income 
- Bank interest payable/(receivable) 

Net finance income 

Year Ended  
31 December 2016 

Year Ended  
31 December 2015 

£000 
-) 
-) 
-) 
-) 

-) 

£000 
                            890 
(1,760) 
(870) 
(32) 

(902) 

2016 
£000 

10 

10 

2016 
£000 

(6) 

(6) 

2015) 
£000) 

8 

8 

2015) 
£000) 

4 

4 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 37 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

9.  EMPLOYEES 

including  executive  and  non-executive 

Employee  costs 
directors during the year amounted to: 
Wages and salaries 
Social security costs 
Other pension costs 

Share based payments 

The  average  number  of  persons  employed  during  the  year 
including executive directors analysed by category was made 
up as follows: 

Sales and marketing 
Product development and support 
Administration 

2016 
£000 

73 
4 
- 

- 

77 

2016 
Number 

- 
- 
3 

3 

2015) 
£000) 

394 
34 
3 

31 

462 

2015 
Number 

2 
12 
4 

18 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 38 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

9 . EMPLOYEES (continued) 

The total remuneration of directors was as follows: 

Fees 
Remuneration as executives (including benefits in 
kind) 
Pension contributions 
Share based payments 

2016 
£000 

14 
59 

- 
- 

73 

No remuneration is paid directly by the Group for the services of the other executive director. There is currently no 
pension provision for any of the directors and therefore no pension is accrued to them. 

Details of the directors’ interests in the share capital of the company together with further details of the directors’ 
remuneration are contained in the Remuneration Report on pages 15 to 16. 

There are no amounts of compensation payable to key management. 

10.  TAXATION ON PROFIT 

a)   Analysis of charge in the year 

Current taxation  

UK corporation tax on profits for the year 
Adjustments in respect of previous periods 

Total current taxation 

Deferred taxation 

Origination and reversal of temporary differences  

Taxation expense 

2016 
£000 

-)) 
-)) 

-)) 

-)) 

-)) 

2015 
£000 

9 
45 

- 
31 

85 

2015 
£000 

-)) 
(13)) 

(13)) 

(-)) 

(13)) 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 39 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

10.  TAXATION ON PROFIT (continued) 

b)   Factors affecting charge in the year 

(Loss)/Profit on ordinary activities before taxation 

Tax at UK corporation tax rate 20% (2015:20%) 

Effect of: 

Depreciation in excess of capital allowances 
Utilisation of tax losses not recognised for deferred 
taxation 
Adjustments in respect of previous period 
Deferred tax movement 

2016 
£000 

(22) 

-) 

-) 

-) 
-) 
-) 

-) 

2015 
£000 

(1,066) 

(213) 

-) 

213 
(13) 
(-) 

(13) 

The Company has estimated tax losses to carry forward of £4,755,000 (2015: £4,733,000) which may be available 
for offset against future profits.  

11.  EARNINGS PER SHARE 

The inputs to the earnings per share calculation are shown below: 

Weighted average ordinary shares in issue during the year 
Potentially diluted share options under the Group’s share 
option schemes 
Weighted average ordinary shares for diluted earnings per 
share  

Loss attributable to shareholders 

Continuing operations 
Discontinued operations 

2016 
Number 

138,660,439 

- 
138,660,439 

£ 

22,000 
-) 

22,000 

2015 
Number 

46,370,034 

- 
46,370,034 

£ 

151,000 
902,000 

1,053,000 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 40 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

11.  EARNINGS PER SHARE (continued) 

The calculation of basic earnings per ordinary share is based on the profit for the period attributable to equity holders 
of the parent and the weighted average number of ordinary shares in issue during the year. 

Diluted earnings per share is calculated by adjusting the weighted average number of ordinary shares outstanding to 
assume conversion of all dilutive share options. 

In  view  of  the  group  loss  for  the  year,  share  warrants  and  options  to  subscribe  for  shares  in  the  company  are  anti-
dilutive and therefore diluted earnings per share is the same as basic loss per share. 

12.  PROPERTY, PLANT AND EQUIPMENT 

GROUP 

Freehold land 
and buildings 

Cost 
At beginning of year 
Additions 
Disposals 
Foreign currency exchange 
difference 

At end of year 

Depreciation 
At beginning of year 
Charge for the year 
Eliminated by disposals 

At end of year 

Net book value 
At end of year 

2016 
£000 

-) 
-) 
-) 
-) 

-) 

-) 
-) 
-) 

-) 

-) 

2015 
£000 

392) 
-) 
(392) 
-) 

-) 

43) 
3) 
(46)) 

-) 

-) 

Plant, Office and 
computer equipment 
and motor vans 
2015 
£000 

2016 
£000 

2016 
£000 

-) 
-) 
-) 
-) 

-) 

-) 
-) 
-) 

-) 

-) 

886) 
226) 
(1,112)) 
-) 

-) 

619) 
227) 
(846)) 

-) 

-) 

-) 
-) 
-) 
-) 

-) 

-) 
-) 
-) 

-) 

-) 

Total 

2015 
£000 

1,278) 
226) 
(1,504) 
-) 

-) 

662) 
230) 
(892)) 

-) 

-) 

  There  are  no  restrictions  on  title  and  no  assets  above  have  been  pledged  as  security.  In  addition,  there  were  no 
  contractual commitments for the acquisition of property or other assets.  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 41 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

12.   PROPERTY, PLANT AND EQUIPMENT (continued) 

COMPANY 

Cost 
At beginning of year 
Additions 
Disposals 

At end of year 

Depreciation 
At beginning of year 
Charge for year 
Eliminated on disposal 

At end of year 

Net book value 
At end of year 

GROUP AND COMPANY 

Freehold land 
and buildings 

Plant  and 
equipment 

2016 
£000 

-) 
-) 
-) 

-) 

-) 
-) 
-) 

-) 

-) 

2015 
£000 

120) 
-) 
(120) 

-) 

43) 
3) 
(46) 

-) 

-) 

2016 
£000 

-) 
-) 
-) 

-)) 

-) 
-) 
-) 

-)) 

-)) 

2015 
£000 

853)) 
228)) 
(1,081)) 

-)) 

586)) 
229)) 
(815)) 

-)) 

-)) 

Total 

2015 
£000 

973)) 
228)) 
(1,201)) 

-)) 

629)) 
232)) 
(861)) 

-)) 

-)) 

2016 
£000 

-) 
-) 
-) 

-)) 

-) 
-) 
-) 

-)) 

-)) 

The aggregate amounts at which freehold land and buildings would have been shown in the financial statements had 
they not been revalued is the same as historical cost. 

The  freehold  land  and  buildings  which  were  owned  by  the  company  are  located  in  Crediton,  Devon  and  were      
revalued  on  the  basis  of  market  value  and  rental  value.  The  valuation  report,  dated  20  September  2004,  quotes a 
market  value  that  agreed  to  the  original  cost  of  £120,000.  The  directors  did  not  consider  this  valuation  to  be 
materially different as at 31 December 2014 and therefore that the carrying cost was not materially different from 
the fair value. The asset was fully disposed with the subsidiaries in the prior year. 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 42 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

13.  INVESTMENTS 

An investment was made on 7 December 2015 where 50,000,000 0.1p placing shares were purchased in Glenwick 
Plc for £50,000. This gives rise to a 3.63% holding in the company this was disposed of 8 January 2016. 

An investment was made on 1 March 2016 where 49% of N4 Pharma Limited was purchased. 

The directors are of the opinion that there is no impairment adjustment required in respect of the investments in N4 
Pharma Limited, on the assumption that N4 Pharma will have sufficient resources to complete their R&D activities. 
In  the  event  that  N4  Pharma is  unable  to  achieve  its  financial  forecasts,  adjustments  will  have  to  be  made  to  the 
statement of financial position of the group and company to reduce the value of the asset to its recoverable amounts, 
to provide for future liabilities that might arise and to reclassify non-current assets as current assets. 

The  directors  have  taken  the  view  that  N4  Pharma  Limited  will  not  be  deemed  an  associate  company  for  the 
purposes of equity accounting. 

14.  INVESTMENTS IN SUBSIDIARY UNDERTAKINGS 

COMPANY 

Cost 
At beginning of year 
Disposals 

At end of year 

Impairment 
At beginning of year 
Disposals 

At end of year 

Net book value 
At end of year 

At beginning of year 

2016 
£000 

-) 
-) 

-) 

-) 
-) 

-) 

-) 

-) 

2015 
£000 

2,918) 
(2,918) 

-) 

2,626) 
(2,626) 

-) 

-) 

292) 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 43 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

15.  INVESTMENTS IN SUBSIDIARY UNDERTAKINGS  

COMPANY(continued) 

The  principal  subsidiary  undertakings  were  all  wholly  owned  by  the  company  until  the  disposal  in  2015,  were 
consolidated and included the following: 

Subsidiary undertakings 

Principal activity 

Class of share 

Incorporated in England and Wales: 

UTN Solutions (North) Limited 

Merchandising of electric bicycles and other products 

Ordinary 

Cognito Software Limited 

Marketing and support of computer application software 

Ordinary 

Incorporated in Italy: 

Tre-Sol Italia srl 

Development of solar power park 

Ordinary 

The following undertakings, which are all wholly owned by Tre-Sol Italia srl and incorporated in Italy, are consolidated and 
include the following 

Ultima Italia srl 
Harlicon srl 
Leccesolar srl 

Development of solar power park 
Development of solar power park 
Development of solar power park 

The company disposed of all subsidiary undertakings on 14 October 2015. 

Ordinary 
Ordinary 
Ordinary 

16.  INVENTORY 

Investments 

Inventories comprise of investments made.  

GROUP 

2016 
£000 

232 

2015 
£000 

-) 

COMPANY 
2016 
£000 

232) 

2015 
£000 

-) 

It  is  the  opinion  of  the  directors  that  no  impairment  to  the  carrying  amount  of  inventory  investments  is  considered 
necessary. 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 44 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

17.  TRADE AND OTHER RECEIVABLES 

GROUP 

2016 
£000 

2015 
£000 

COMPANY 
2016 
£000 

2015 
£000 

Non Current Assets 
Other receivables (see note 26)  

Trade receivables – net 
Amounts owed by Group undertakings 
Owed by related party (see note 26) 
Other receivables  
Tax recoverable 
Prepayments and accrued income 

215 

- 
- 
- 
195 
-) 
2 

412 

- 

- 
- 
- 
1 
9 
11 

21 

215 

- 
- 
- 
195 
-) 
2 

412 

- 

- 
- 
- 
1 
9 
11 

21 

The directors do not consider there to be any material difference between the fair values of trade and other receivables 
and the amounts shown above. The trade and other receivables of the company and the Group are all denominated in 
pounds sterling. The Group’s main credit risk relates to trade receivables. No collateral is held as security against these 
receivables and the carrying value approximates to the fair value. 

Long term other receivables relates to the loan to N4 Pharma Limited. 

Trade receivables that are less than three months past due are not considered impaired. As of 31 December 2016, trade 
receivables of £Nil (2015: £Nil) were past due but not impaired. These relate to a number of independent customers 
for whom there is no recent history of default. The ageing analysis of these trade receivables is as follows:  

Up to 3 months 
Over 3 months 

GROUP 

2016 
£000 

-) 
-) 

-) 

2015 
£000 

-) 
-) 

-) 

COMPANY 
2016 
£000 

2015 
£000 

-) 
-) 

-) 

-) 
-) 

-) 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 45 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

18.  CASH AND CASH EQUIVALENTS 

Cash at bank and on hand 
Short-term bank deposits 

19.  TRADE AND OTHER PAYABLES 

GROUP 

2016 
£000 

172 
- 

172 

2015 
£000 

587 
- 

587 

COMPANY 
2016 
£000 

172 
- 

172 

2015 
£000 

587 
- 

587 

GROUP 

2016 
£000 

2015 
£000 

COMPANY 
2016 
£000 

2015 
£000 

Bank overdraft 
Trade payables 
Amounts due to Group undertakings 
Owed to related party (see note 24) 

- 
- 
- 
- 

- 

- 
- 
- 
- 

- 

-) 
- 
- 
- 

- 

- 
- 
- 
- 

- 

The directors consider that the carrying value of trade and other payables approximates to their fair value. 

20.  FINANCIAL INSTRUMENTS 

The Group’s financial instruments,  from which financial instrument risk arises, comprise cash and cash  equivalents, 
trade receivables and trade payables that arise directly from its operations. The main financial instrument risks arising 
from and impacted by, the financial assets and liabilities of the Group are credit risk, cash flow interest rate risk and 
liquidity risk. The Board reviews and agrees policies for managing these risks and they are summarised below. 

The  Group  does  not  hold  any  derivative  financial  instruments.  The  Group’s  financial  assets  and  liabilities  are 
measured at amortised cost. 

A debenture is in place for National Westminster Bank PLC on all monies due from the company to the chargee on 
any  account  whatsoever  secured  on  a  fixed  and  floating  charges  over  the  undertaking  and  all  property  and  assets 
present and future including goodwill uncalled capital buildings fixtures plant and machinery. 

The principal financial assets of the Group are trade receivables and cash at bank. Cash is held in sterling only in either 
a current account or on short-term deposit. The amounts being as follows: 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 46 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

20.   FINANCIAL INSTRUMENTS (continued) 

Financial assets by category 

GROUP 
2016 

Non current assets 
Other receivables 
Current Assets 
Cash at bank 
Trade and other receivables 
Prepayments 
Tax recovery 

2015 
Cash at bank 
Trade and other receivables 
Prepayments 
Tax recovery 

Loans and 
receivables 
£000 

Non-financial 
Assets 
£000 

Balance sheet 

£000 

215 

172 
195 
2 
- 

584 

587 
- 
- 
10 

597 

- 
- 
- 
- 

- 

- 
- 
11 
- 

11 

215 

172 
195 
2 
- 

584 

587 
- 
11 
10 

608 

Trade receivables arise directly from  the Group’s operations and do not carry any interest. All  cash balances  attract 
interest  at  floating  rates  that  vary  with  United  Kingdom  bank  base  rates.  The  Group  does  not  have  any  undrawn 
borrowing facilities. 

COMPANY 
2016 

Non current assets 
Other receivables 
Current Assets 
Cash at bank 
Trade and other receivables 
Amounts owed by Group undertaking 
Prepayments 

2015 
Cash at bank 
Trade and other receivables 
Amounts owed by Group undertaking 
Prepayments 

Loans and 
receivables 
£000 

Non-financial 
Assets 
£000 

Balance sheet 

£000 

215 

172 
195 
- 
2 

584 

587 
- 
- 
10 

597 

- 
- 
- 
- 

- 

- 
- 
11 
- 

11 

215 

172 
195 
- 
2 

584 

587 
- 
11 
10 

608 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 47 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2015 

20.  FINANCIAL INSTRUMENTS (continued) 

GROUP 
2016 

Bank overdraft 
Trade payables 
Owed to related party 
VAT and tax payable 
Accruals and deferred income 

2015 
Bank overdraft 
Trade payables 
Owed to related party 
VAT and tax payable 
Accruals and deferred income 

COMPANY 
2016 
Bank overdraft 
Trade payables 
Amounts due to group undertakings 
Owed to related party 
VAT and tax payable 
Accruals  

2015 
Bank overdraft 
Trade payables 
Amounts due to group undertakings 
Owed to related party 
VAT and tax payable 
Accruals  

Other financial 
liabilities 
£000 

Non-financial 
liabilities 
£000 

Balance sheet 

£000 

- 
- 
- 
- 
- 

- 

- 
- 
- 
- 
- 

- 

- 
- 
- 
- 
- 
- 

- 

- 
- 
- 
- 
- 
- 

- 

- 
- 
- 
- 
77 

77 

- 
- 
- 
- 
17 

17 

- 
- 
- 
- 
- 
77 

77 

- 
- 
- 
- 
- 
17 

17 

- 
- 
- 
- 
77 

77 

- 
- 
- 
- 
17 

17 

- 
- 
- 
- 
- 
77 

77 

- 
- 
- 
- 
- 
17 

17 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 48 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

20.  FINANCIAL INSTRUMENTS (continued) 

Credit risk 
The  Group’s  credit  risk  is  primarily  attributable  to  its  trade  receivables.  Exposures  to  credit  risk  are  minimised  by 
employing  effective  credit  management  policies  and  procedures.  Only  customers  known  to  the  Group  are  granted 
credit terms. Annual fees for software licences and support agreements are payable in advance and require a uniquely 
numbered “valid licence key” to operate. 

Cash flow interest rate risk 
The  Group  is  cash  positive  and  places  its  balance  on  short-term  deposits  with  National  Westminster  Bank  Plc. 
Variable rate interest receivable is based on United Kingdom bank base rates and therefore changes in interest rates 
may affect the return on cash balances. No interest is received on any of the Group’s other assets or receivables. The 
Group does not have any loans, bank borrowings or other interest bearing payables. 

Liquidity risk 
It is the Group’s policy to maintain sufficient cash resources to meet its short-term liabilities. 

Price risk 
The Group does not hold any listed security investments and therefore has no exposure to securities price risk. 

Fair values 
The Directors consider that there is no material difference between the book value and the fair value of the financial 
instruments at 31 December 2016 and 31 December 2015. 

Capital risk management 
The  Group  considers  its  capital  to  comprise  its  ordinary  and  deferred  share  capital,  share  premium  account  and 
accumulated retained losses. 

The Group’s objectives when managing capital are to safeguard the Group’s ability to continue as a going concern in 
order  to  provide  returns  for  shareholders  and  benefits  for  other  stakeholders  and  to  maintain  an  optimal  capital 
structure to reduce the cost of capital.  In order to maintain or adjust the capital structure, the Group may adjust the 
amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt. 

The Group considers equity funding as the most appropriate form of capital for the Group, but keeps this under review 
taking into account the risks, costs and benefits to equity shareholders of introducing debt. 

21.   DEFERRED TAX ASSET 

The Company has estimated tax losses of £4,755,000 as at 31 December 2016 (2015: £4,733,000) which have not been 
recognised for deferred tax purposes as these are recognised only to the extent that it is probable that future taxable 
utilised. 
the 
profits  will 

against  which 

differences 

temporary 

available 

can 

be 

be 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 49 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

22.  CALLED UP SHARE CAPITAL 

Allotted, called up and fully paid 
181,956,558 ordinary shares of 0.01p each 
137,674,431 deferred shares of 4p each 
279,176,540 placing shares of 0.099p each 

2016 
£000 

182 
5,507 
2,764 

8,453 

2015 
£000 

138 
5,507 
2,764 

8,409 

On  the  1  March  2016,  the  Company  issued  24,272,807  ordinary  shares  of  0.1p  at  a  price  of  1p  to  N  Theobald  in 
relation to a share for share exchange relating to the acquisition of N4 Pharma (refer to note 13). 

The  Company  had  also  issued  15,000,000  and  4,051,815  ordinary  shares  of  0.1p  for  the  price  of  1p  and  0.7p  
respectively on 13 June 2016 and 23 June 2016  . 

The deferred shares have no right to dividends nor do the holders thereof have the right to receive notice of or to attend 
or vote at any General Meeting of the company. On a return of capital on a winding up of the company, the holders of 
the deferred shares shall only be entitled to receive the amount paid up on such shares after the holders of the ordinary 
shares have received the sum of £1,000,000 for each ordinary share held by them. 

Ultima Networks Plc 2004 Share Option Scheme 
The scheme was approved by the AGM held on 28 May 2004. No options to subscribe for ordinary shares of 1p each 
have been granted under this scheme. 

Ultima Networks Plc 2012 Share Option Scheme 
The  scheme  was  approved  by  the  AGM  held  on  26  June  2012,  being  the  Ultima  Networks  Plc  2012  Share  Option 
Scheme, but no options to subscribe for ordinary shares of 1p each have been granted to date.  

Executive Share Option Schemes 
Options  to  subscribe  for  ordinary  shares  of  1p  each  are  exercisable  in  accordance  with  the  1994  Microvitec  Inland 
Revenue  Approved  Executive  Share  Option  Scheme.  During  the  year  ended  31  December  2014,  no  options  were 
granted, no options were exercised and no options lapsed.  

23.  CAPITAL COMMITMENTS 

Contracted capital expenditure 

GROUP 

2016 
£000 

- 

2015 
£000 

- 

COMPANY 
2016 
£000 

- 

2015 
£000 

- 

24.  FUTURE OPERATING LEASE COMMITMENT 

There are no operating lease commitments at the balance sheet date. (2015: £Nil) 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 50 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

25.  PENSIONS 

The Group did not contribute to personal pension schemes (defined contribution). No contributions were paid 
in respect of the directors. No amounts were accrued or prepaid at the year end (2015: £Nil) 

26.  RELATED PARTY TRANSACTION 

Gavin  Burnell  and  Luke  Cairns  were  granted  10,804,840  and  2,701,210  share  options  respectively  on  14 
October 2015. No director has granted or exercised any share options during this or the previous year nor did 
any lapse.  

Gavin  Burnell  owed  the  Company  £37,299  (2015:  £Nil)  at  the  year  end.  This  amount  was  repaid  in  full 
within 9 months of the year end. 

During the year the Group made purchases from Akhter Group Limited totalling £Nil (2015: £43,000 of this 
amount, £Nil (2015: £Nil) was payable to Akhter Group Limited as at 31 December 2016. The purchases can 
be analysed as follows:  

Group company 

Ultima Networks 
UTN Solutions (North) 
Cognito Software 

Total 

2016 
£000 

2015 
£000 

Description of purchases 

- 
- 
- 

- 

-  Executive management services and project costs 

43  Rent and carriage costs 

-  Pensions and carriage costs 

43 

Last year the Group made sales to Akhter Group Limited totalling £Nil (2015: £144,000) of this amount, £Nil 
(2015: £Nil) was payable by Akhter Group Limited as at 31 December 2016.  

A loan of £209,000 was made to N4 Pharma Limited a company which an interest of 49% is held. The loan is 
due to be repaid on 1 March 2020 unless repaid earlier at the mutual agreement of both parties and accrues 
interest at 5% per annum. Interest of £5,949 has been rolled up into the loan. 

Onzima purchased 2,727,273 shares in Lionsgold Limited previously named Kolar Gold Limited on 12 July 
2016 a company which Luke Cairns is a director.. 

SHARE BASED PAYMENT CHARGES  

The  Company  had  granted  Ordinary  Share  options  to  its  directors  during  the  previous  year  that  may  be 
exercised within ten years in whole or in part from the date of the grant at an exercise price of 0.7p per share. 
No additional options have been granted in the year. 

The Black Scholes method was used to calculate the fair value of options at the date of grant.   

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 51 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

SHARE BASED PAYMENT CHARGES (continued) 

The table below lists the inputs to the model used for the options granted during the year: 

Weighted average share price at date of grant 
Weighted average exercise price 
Expected volatility 
Risk free rate 

0.9 pence 
0.7 pence 
50% 
1% 

A total share based payment charge of £Nil was expensed in 2016 (2015: £30,812) in respect of the options 
granted to the directors. 

The share options held as at 31 December 2016 are set out in the table below: 

Granted 
during the 
period 

Exercised 
during the 
period 

Outstanding at 
31 December 
2016 

Option Price 

Exercisable on 
or before 

G Burnell 
L Cairns 

Total Options 

10,804,840 
2,701,210 

13,506,050 

— 
— 

— 

10,804,840 
2,701,210 

13,506,050 

0.7p 
0.7p 

25 Oct 2025 
25 Oct 2025 

Note: A detailed breakdown of directors’ options is set out in the Report on Directors’ Remuneration. 

Additionally,  the  company  has  issued  4,051,805  warrants  to  its  brokers,  Peterhouse  Corporate  Finance,  for 
the subscription of Ordinary Shares which may be exercised at any time up to 22 August 2019 at a price of 
0.7p per share. This was fully excised on 23 June 2016. 

27.  CONTINGENT LIABILITY 

The Company had no contingent liabilities. 

28.  CONTROLLING PARTY 

In the opinion of the directors, there is no ultimate controlling party. 

29.  PROVISIONS 

No provisions have been made in these accounts. There is no deferred tax in the current year. 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ONZIMA VENTURES PLC 

Page 52 

NOTES TO THE FINANCIAL STATEMENTS 
FOR THE YEAR ENDED 31 DECEMBER 2016 

30.  SUBSEQUENT EVENTS   

On 17 January 2017, the Company announced that it had agreed in principle terms conditionally to acquire 
the 51 per cent. of the issued shares of N4 Pharma which it did not already own. The consideration for the 
Proposed Acquisition will be satisfied by the issue of 36,409,210 new ordinary shares of 0.1p each in the 
capital of Onzima. It is intended that at the same time the Company will seek to raise approximately £3.0 
million  by  way  of  a  placing  of  new  Ordinary  Shares  plus  an  open  offer  of  up  to  £1.0  million  to  fund 
development of additional patented reformulations of a wider range of generic drugs, to undertake clinical 
trials  for  the  Company's  reformulation  of  sildenafil  and  for  working  capital  purposes.  A  further  loan  of 
£100,000 has been made subject to an annual rate of interest of 5%. 

The Proposed Acquisition will be classified as a reverse takeover under the AIM Rules for Companies and, 
as a result, is subject to the publication of an admission document in respect of the Company as enlarged by 
N4  Pharma  setting  out  full  details  of  the  Proposed  Acquisition  and  convening  a  general  meeting  of  the 
Company where shareholders' approval will be sought for, among other things, the Proposed Acquisition, 
the share reorganisation, and to change the Company's name to N4 Pharma plc.